Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:APGENASDAQ:ETONNASDAQ:HRMY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$36.06+2.0%$31.92$23.42▼$62.58$2.09B0.73653,612 shs258,713 shsAPGEApogee Therapeutics$47.55+7.3%$40.36$26.20▼$63.50$2.19B1.47565,403 shs507,962 shsETONEton Pharmaceuticals$14.53+0.3%$16.55$3.25▼$21.48$387.52M1.18258,742 shs243,255 shsHRMYHarmony Biosciences$32.09-0.1%$33.20$26.47▼$41.61$1.85B0.83631,656 shs287,680 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals0.00%+7.72%+5.95%+39.97%-14.20%APGEApogee Therapeutics0.00%+9.61%+30.27%+47.12%+26.80%ETONEton Pharmaceuticals0.00%+3.68%-14.31%+22.78%+341.49%HRMYHarmony Biosciences0.00%+0.34%-8.73%+9.67%+3.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.1244 of 5 stars3.41.00.04.32.00.81.9APGEApogee Therapeutics2.9046 of 5 stars3.52.00.00.02.54.20.0ETONEton Pharmaceuticals2.5141 of 5 stars3.53.00.00.01.41.70.6HRMYHarmony Biosciences4.7998 of 5 stars4.61.00.00.02.83.34.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.71Moderate Buy$58.6062.53% UpsideAPGEApogee Therapeutics 3.00Buy$95.80101.47% UpsideETONEton Pharmaceuticals 3.00Buy$29.67104.25% UpsideHRMYHarmony Biosciences 3.13Buy$53.6367.11% UpsideCurrent Analyst Ratings BreakdownLatest ETON, APGE, AGIO, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025APGEApogee TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$116.006/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/29/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $35.005/16/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $26.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.005/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M57.21N/AN/A$27.02 per share1.33APGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/AETONEton Pharmaceuticals$39.01M9.99N/AN/A$0.94 per share15.45HRMYHarmony Biosciences$714.73M2.58$2.94 per share10.91$11.56 per share2.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.243.21N/AN/A1,798.26%-2.75%-2.52%7/30/2025 (Estimated)APGEApogee Therapeutics-$182.15M-$3.60N/AN/AN/AN/A-28.35%-26.98%8/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.18N/A29.05N/A-9.49%-3.15%-1.08%8/4/2025 (Estimated)HRMYHarmony Biosciences$145.49M$2.6212.2710.320.4820.53%24.32%15.92%8/5/2025 (Estimated)Latest ETON, APGE, AGIO, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ETONEton Pharmaceuticals$0.09$0.07-$0.02-$0.06$14.33 million$17.28 million5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 million5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A18.5017.93APGEApogee TherapeuticsN/A15.8215.82ETONEton Pharmaceuticals1.231.971.43HRMYHarmony Biosciences0.223.673.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AAPGEApogee Therapeutics79.04%ETONEton Pharmaceuticals27.86%HRMYHarmony Biosciences86.23%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%APGEApogee Therapeutics42.77%ETONEton Pharmaceuticals16.03%HRMYHarmony Biosciences23.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million55.43 millionOptionableAPGEApogee Therapeutics9146.05 million26.35 millionOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionableETON, APGE, AGIO, and HRMY HeadlinesRecent News About These CompaniesHere's Why Harmony Biosciences Is an Unconventional Cannabis InvestmentJuly 4 at 8:50 AM | zacks.comFirst Week of August 15th Options Trading For Harmony Biosciences Holdings (HRMY) - NasdaqJune 24, 2025 | nasdaq.comNeedham Reiterates a Buy Rating on Harmony Biosciences (HRMY)June 24, 2025 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Rating of "Buy" by BrokeragesJune 21, 2025 | marketbeat.comExchange Traded Concepts LLC Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 20, 2025 | marketbeat.comHarmony Biosciences obtains favorable settlement in litigation over generic WakixJune 19, 2025 | drugstorenews.comDSG Americas Securities LLC Has $1.17 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 18, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Sees Significant Increase in Short InterestJune 17, 2025 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Trading Down 4.5% - Should You Sell?June 12, 2025 | marketbeat.com77,867 Shares in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Purchased by CX InstitutionalJune 12, 2025 | marketbeat.comMillennium Management LLC Has $218,000 Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 12, 2025 | marketbeat.comCantor Fitzgerald Weighs in on HRMY FY2026 EarningsJune 11, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by California State Teachers Retirement SystemJune 10, 2025 | marketbeat.comHarmony Biosciences Holdings, Inc. (HRMY): A Bull Case TheoryJune 9, 2025 | insidermonkey.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bridge City Capital LLCJune 9, 2025 | marketbeat.comHarmony Biosciences Holdings (HRMY) Shares Cross Below 200 DMAJune 7, 2025 | nasdaq.comHarmony Biosciences settles generic drug litigation, strengthens patentJune 6, 2025 | finance.yahoo.comHarmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA LitigationJune 5, 2025 | businesswire.comHennion & Walsh Asset Management Inc. Boosts Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)June 5, 2025 | marketbeat.comHarmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | businesswire.com4HRMY : Where Harmony Biosciences Hldgs Stands With AnalystsJune 2, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETON, APGE, AGIO, and HRMY Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$36.06 +0.71 (+1.99%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$36.06 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Apogee Therapeutics NASDAQ:APGE$47.55 +3.23 (+7.29%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$47.38 -0.17 (-0.37%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$14.52 +0.05 (+0.31%) As of 07/3/2025 03:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Harmony Biosciences NASDAQ:HRMY$32.09 -0.02 (-0.06%) Closing price 07/3/2025 03:51 PM EasternExtended Trading$32.18 +0.09 (+0.28%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
